Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the ccr5 antagonist vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211)

Journal of Acquired Immune Deficiency Syndromes

Volumn 53, Issue 5, 2010, Pages 598-605

  Crawford, Keith W ^a   Li, Chonghua ^b   Keung, Anther ^b   Su, Zhaohui ^c   Hughes, Michael D ^c   Greaves, Wayne ^b   Kuritzkes, Daniel ^d   Gulick, Roy ^e   Flexner, Charles ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

CCR5 antagonists; HIV; Pharmacokinetics pharmacodynamics; Vicriviroc

Indexed keywords

AMPRENAVIR PLUS FOSAMPRENAVIR; ATAZANAVIR; LOPINAVIR; PLACEBO; PROTEINASE INHIBITOR; SAQUINAVIR; TIPRANAVIR; UNCLASSIFIED DRUG; VICRIVIROC; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; VIRUS INHIBITION; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; AREA UNDER CURVE; DOUBLE-BLIND METHOD; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NONLINEAR DYNAMICS; PIPERAZINES; PYRIMIDINES; RECEPTORS, CCR5; RNA, VIRAL; YOUNG ADULT;

EID: 77950255798     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181c9caac     Document Type: Article

References (36)

1. Björndal A, Deng H, Jansson M, et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol. 1997;71:7478-7487.
2. Moore JP, Doms RW. The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci U S A. 2003;100:10598-10602.
3. Simmons G, Wilkinson D, Reeves JD, et al. Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J Virol. 1996; 70:8355-8360.
4. Dong XN, Chen X, Chen Y, et al. HIV type 1 phenotype, tropism, and sequence patterns: association and preference. AIDS Res Hum Retro-viruses. 2005;21:234-238.
5. van't Wout AB, Kootstra NA, Mulder-Kampinga GA, et al. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest. 1994;94: 2060-2067.
6. Connor RI, Sheridan KE, Ceradini D, et al. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med. 1997;185:621-628.
7. Waters L, Mandalia S, Randell P, et al. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin Infect Dis. 2008;46: 1617-1623.
8. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CCR5 structural gene. Science. 1996;273:1856-1862.
9. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996;382:722-725.
10. Tagat JR, McCombie SW, Nazareno D, et al. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4, 6-dimethyl-5- pyrimidinyl)carbonyl]-4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)pheny-l]ethyl-3(S) -methyl-1-piperazinyl]-4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. J Med Chem. 2004;47:2405-2408.
11. Strizki JM, Tremblay C, Xu S, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2005;49:4911-4919.
12. Schürmann D, Fätkenheuer G, Reynes J, et al. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS. 2007;21: 1293-1299.
13. la Porte CJ, Schippers EF, van der Ende M, et al. Pharmacokinetics of once-daily lopinavir/ritonavir and the influence of dose modifications. AIDS. 2005;19:1105-1107.
14. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced subjects: AIDS clinical trials group 5211. J Infect Dis. 2007;196:304-312.
15. Landovitz RJ, Angel JB, Hoffmann C, et al. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J Infect Dis. 2008;198:1113-1122.
16. Weller S, Radomski KM, Lou Y, et al. Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother. 2000;44: 2052-2060.
17. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced subjects. J Acquir Immune Defic Syndr. 2006;43:1-5.
18. McFadyen L, Jacqmin P, Wade J, et al. Mariviroc exposure-efficacy (, 50 copies/ml) analysis in HIV 1-infected treatment näive subjects-ITT population (MERIT study). XVII International AIDS Conference #TUPE 0053, July 2008, Mexico City, Mexico.
19. Rosario MC, Jacqmin P, Dorr P, et al. A pharmacokinetic-pharmacody-namic disease model to predict in vivo antiviral activity of maraviroc. Clin Pharmacol Ther. 2005;78:508-519.
20. Valdez H, Lewis M, Delonge C, et al. Weighted OBT Susceptibility Score (wOBTSS) is a stronger predictor of virologic response at 48 weeks than baseline tropism result in MOTIVATE 1 and 2. ICAAC, 2008, #H-1221; October 2008, Washington, D.C.
21. Keung A, Li C, Fellows K, et al. The pharmacodynamic correlation between vicriviroc plasma levels and virologic suppression. 9th International Workshop on Clinical Pharmacology on HIV Therapy; April 2008; New Orleans, USA.
22. Mould DR, Zhang X, Nieforth K, et al. Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected subjects. Clin Pharmacol Ther. 2005;77:515-528.
23. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated subjects with R5 HIV-1 infection. N Engl J Med. 2008;359: 1429-1441.
24. Reeves J, Han D, Wilkin T, et al. An enhanced version of the Trifle Coreceptor Tropism assay predicts emergence of CXCR4 use in ACTG5211 vicriviroc trial samples. Conference on Retroviruses and Opportunistic Infections, February, 2008, #869, Boston, MA.
25. Saag M, Heera J, Goodrich J. et al. Reanalysis of the MERIT study with the enhanced Trofile assay. Abstract H-1232a. 48th ICAAC, 25-28 October 2008, Washington, DC.
26. Su Z, Gulick R, Krambrink A. Response to vicriviroc in treatment-experienced subjects using an enhanced sensitivity co-receptor tropism assay: reanalysis of AIDS Clinical Trials Group A5211. J Infect Dis. 2009, 200:1724-1728.
27. Westby M, Smith-Burchnell C, Mori J, et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol. 2007;81:2359-2371.
28. Ogert RA, Wojcik L, Buontempo C, et al. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology. 2008;373:387-399.
29. Tsibris AM, Sagar M, Gulick RM, et al., In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol. 2008;82:8210-8214.
30. Kondru R, Zhang J, Ji C, et al. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharmacol. 2008;73:789-800.
31. Westby M, van der Ryst E. CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir Chem Chemother. 2005;16: 339-354.
32. Ghosal A, Ramanathan R, Yuan Y, et al. Liver cytochrome P450 enzymes involved in biotransformation of vicriviroc, a CCR5 receptor antagonist. Drug Metab Dispos. 2007;35:2186-2195.
33. Sansone A, Keung A, Tetteh E, et al. Pharmacokinetics of vicriviroc are not affected in combination with five different protease inhibitors boosted by ritonavir. Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 5-8, 2006. Abstract 582.
34. Sansone A, Keung A, Caceres M, et al. Effect of food on bioavailability of SCH 4 17690 in healthy volunteers. Programs and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, December 16-19, 2005, Washington, DC. Abstract A-1200.
35. Mathias AA, West S, Hui J, et al. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther. 2009;85:64-70.
36. Zingman B, Suleiman J, DeJesus E, et al. Vicriviroc, a next generation CCR5 antagonist, exhibits potent, sustained suppression of viral replication in treatment-experienced adults: VICTOR-E1 48-week results. Conference on Retroviruses and Opportunistic Infections, 2008, #39L, Boston, MA